Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03158428 · ClinicalTrials.gov registry record · NA

CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products

A NA study of Tobacco Use, sponsored by RAI Services Company.

Completed
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT03158428: Completed NA study of Tobacco Use, sponsored by RAI Services Company.

NCT03158428 is a NA study of Tobacco Use that has completed, run by RAI Services Company. The registered enrollment target is 55 participants, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03158428, a NA study of Tobacco Use, has completed, sponsored by RAI Services Company.

COMPLETED
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate exposure to tobacco constituents from two moist snuff products, and provide a basis for comparing mouth-level exposure (MLE) in moist snuff users after use of each of the two moist snuff products.

Conditions Studied

Interventions

  • OTHER CSD170202AA
  • OTHER CSD170202AB

Study Locations (1)

Georgia

  • Clinical Research Atlanta - Stockbridge

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2017-05-08
Est. Completion 2017-07-25
Phase NA
RAI Services Company

42 total trials

What the finished NCT03158428 record still lists

NCT03158428 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 378-participant average among 76 other Tobacco Use trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which CSD170202AA is the first listed.

NCT03158428 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT03158428 about?

NCT03158428 is a clinical study titled "CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products". This study will evaluate exposure to tobacco constituents from two moist snuff products, and provide a basis for comparing mouth-level exposure (MLE) in moist snuff users after use of each of the two moist snuff products.

What is the current status of trial NCT03158428?

This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2017-05-08. Estimated completion is 2017-07-25.

What conditions does trial NCT03158428 study?

This clinical trial studies the following conditions: Tobacco Use.

What interventions are being tested in trial NCT03158428?

The interventions under investigation include: CSD170202AA (OTHER), CSD170202AB (OTHER).

Who is sponsoring clinical trial NCT03158428?

This trial is sponsored by RAI Services Company, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03158428 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03158428's enrollment target sits among peer trials

55 53rd of 76 higher than 24 of 76 other Tobacco Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01638676 · 55 participants · Phase 1

    A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

  • NCT01906385 · 55 participants · Phase 1

    Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

  • NCT03007030 · 55 participants · Phase 2

    Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

  • NCT03152058 · 55 participants · Phase 2

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03158428, the US trial registry maintained by the National Library of Medicine. NCT03158428 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.